Journal of Bone and Mineral Metabolism

, Volume 27, Issue 1, pp 110–113

Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis

Short Communication

DOI: 10.1007/s00774-008-0001-2

Cite this article as:
Montella, L., Merola, C., Merola, G. et al. J Bone Miner Metab (2009) 27: 110. doi:10.1007/s00774-008-0001-2


Langerhans cell histiocytosis (LCH) is a rare disease, probably an atypical myeloproliferative syndrome, with variable clinical presentation and behavior. In this report, we focus on bone involvement by LCH and treatment with zoledronic acid in six patients as they progressed after chemotherapy and radiotherapy. Zoledronic acid appeared safe and produced significant relief in pain.


Langerhans cell histiocytosisBone lesionsZoledronic acid

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer 2008

Authors and Affiliations

  1. 1.Medical Oncology UnitS. Giovanni di Dio HospitalNaplesItaly
  2. 2.Casa di Cura Villa Maria, Mirabella EclanoAvellinoItaly
  3. 3.Molecular and Clinical Endocrinology and Oncology DepartmentFederico II UniversityNaplesItaly